Pasithea Therapeutics Corp. — Director's Dealing 2024

Apr 6, 2024

SEC Form 4/A — Form 4/A

Issuer: Pasithea Therapeutics Corp. (KTTA)
CIK: 0001841330
Period of Report: 2024-03-01

Reporting Person: Currie Graeme Martin (Chief Development Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-03-01	Stock Option (right to buy)	$8.13	A	5938	Acquired	2034-02-28	Common Stock (5938)	Direct

Footnotes

F1: The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on March 1, 2024, was $8.13 per share.

F2: The option award (the "Option") was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The Option fully vested upon issuance and became exercisable on March 1, 2024.